Micrograms, milligrams and international units

Milligrams and micrograms are SI-derived units of mass, not units of biological activity or the SI amount of substance. Mass can be established by weighing, while suitable physicochemical methods such as quantitative amino acid analysis can determine protein content. Equal declared masses do not, by themselves, establish equal molecular amounts, integrity or activity.

That is both the strength and the limit of the measurement. Human growth hormone’s principal form has 191 amino acids and a molecular mass of about 22,125 Da. Oxidation and deamidation can change molecular mass, and dimerization changes the mass of an individual assembly, but weighing a bulk sample does not distinguish the proportions of intact, modified or aggregated forms. Those distinctions can matter in research measurements of receptor interaction.

The international unit is not an SI unit. It is assigned by convention to a defined reference preparation, such as a coded batch of freeze-dried ampoules established through a WHO expert process. Other materials are expressed relative to that standard through an appropriate comparative assay rather than by directly weighing an IU.

Two consequences follow. An IU result describes a relationship between the tested material, the reference and the assay, rather than an intrinsic mass constant of the molecule. When a reference batch is replaced, a collaborative study can establish continuity between the previous and replacement standards; that evidence supports the continuity of the scale.

Before recombinant material was available, pituitary-derived growth hormone preparations contained a mixture of the principal form, size variants, deamidated material and other hormones. Weighing that mixture did not establish how much intact hormone was present, so biological response became central to the measurement scale.

An international collaborative study calibrated candidate growth hormone bioassay standards across 22 laboratories in 10 countries using in vivo, radioreceptor and immunoassay methods. The in vivo estimates varied between laboratories, and this heterogeneity became part of the later standardization discussion.

Rodent studies also characterized the bioassay itself. Work using body-weight gain in dwarf lit/lit mice compared performance with the classic hypophysectomized-rat assay and evaluated statistical precision in a short factorial format. In this historical context, a reported IU value depended on a biological response curve and statistical comparison rather than a balance alone.

Recombinant production supplied a molecule with a defined sequence whose protein content could be evaluated by quantitative amino acid analysis. This enabled physicochemical and biological calibration of the same reference preparation. The international somatropin standard was established through this type of collaborative characterization, with protein content and assigned activity described in parallel.

A practical consequence was a shift in reporting and calibration. The consensus statement on standardizing growth hormone and IGF-I assays recommends mass-based reporting and calibration against appropriate commutable recombinant reference material, aiming to make results for the same sample comparable across laboratories.

A factor relating IU to milligrams is not automatically a universal constant for every preparation called human growth hormone. It reflects an assigned or measured relationship for defined material under an applicable specification. Specific activity belongs to the characterized preparation and its reference framework, not merely to the molecule’s familiar name.

There is also a structural reason to examine the actual material. The approximately 22,125-Da value describes the principal 191-residue isoform, while real samples can contain variants that ligand-binding assays recognize differently. Immunoaffinity capture followed by tandem mass spectrometry was developed to selectively quantify the principal isoform because such differences can contribute to disagreement between assays.

A number printed in IU therefore leaves several questions unanswered.

The catalog makes this distinction explicit. HGH is presented as 8 IU, with the corresponding field labeled Activity rather than Mass. Identity information separately includes the 191-residue chain, approximate 22,125-Da mass, CAS identifier and molecular formula. The catalog label should not be mistaken for independent verification of a particular batch’s activity.

Two neighboring references illustrate the difference. HGH Fragment 176–191 represents 16 C-terminal residues and is listed in milligrams; IGF-1 LR3, with a listed molecular mass around 9,111 Da, is also expressed by mass. The catalog does not assign these materials the intact HGH international activity scale. IU labeling is not a hierarchy of compounds; it reflects a defined activity-reference framework that must actually apply to the material.

Record the original unit without silently normalizing it. If the label says IU, retain IU; if it says milligrams, retain milligrams. Converting merely to make a table look uniform can create an unsupported value that survives the experiment and is later cited as though measured.

When an experiment genuinely requires an equivalence, seek the applicable material documentation: batch-specific characterization or a justified specification, the declared reference standard, assay method and uncertainty or confidence information where available. Potency in this setting is the outcome of a comparative assay, not a generic number copied from a table. Without a defensible documented relationship, the conversion remains unsupported.